Press coverage about Alnylam Pharmaceuticals (NASDAQ:ALNY) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alnylam Pharmaceuticals earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.502253145574 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Alnylam Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares (finance.yahoo.com)
- Alnylam Pharmaceuticals : Announces Successful Outcome Following FDA Type A Meeting to Discuss Fitusiran Program in Hemophilia (4-traders.com)
- Why is Alnylam's (ALNY) Stock Up More Than 200% this Year? (finance.yahoo.com)
- Alnylam Pharmaceuticals, Inc. (ALNY) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Why is Alnylam’s (ALNY) Stock Up More Than 200% this Year? (zacks.com)
Alnylam Pharmaceuticals (NASDAQ ALNY) traded up $0.43 during trading hours on Friday, hitting $126.38. 1,234,400 shares of the stock traded hands, compared to its average volume of 1,136,282. Alnylam Pharmaceuticals has a one year low of $35.98 and a one year high of $147.63. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million during the quarter, compared to analyst estimates of $28.15 million. During the same quarter in the previous year, the business earned ($1.21) earnings per share. The business’s quarterly revenue was up 24.8% compared to the same quarter last year. equities research analysts expect that Alnylam Pharmaceuticals will post -5.33 earnings per share for the current year.
A number of research analysts have commented on the stock. Cowen and Company reiterated a “buy” rating and set a $151.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, November 9th. Morgan Stanley increased their price objective on shares of Alnylam Pharmaceuticals from $101.00 to $130.00 and gave the company an “equal weight” rating in a research note on Thursday, November 9th. J P Morgan Chase & Co upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Thursday, November 9th. B. Riley dropped their target price on shares of Alnylam Pharmaceuticals to $220.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. Finally, Barclays PLC increased their target price on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $114.57.
TRADEMARK VIOLATION NOTICE: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://ledgergazette.com/2017/11/17/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-alnylam-pharmaceuticals-alny-stock-price.html.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the transaction, the president now directly owns 165,399 shares in the company, valued at $16,539,900. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, President Barry E. Greene sold 85,316 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $125.00, for a total transaction of $10,664,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 215,797 shares of company stock valued at $25,035,072. Corporate insiders own 4.30% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.